These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1515 related items for PubMed ID: 30528137

  • 21. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK, Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G.
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [Abstract] [Full Text] [Related]

  • 22. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
    Eur J Cancer; 2018 Mar; 91():21-29. PubMed ID: 29331748
    [Abstract] [Full Text] [Related]

  • 24. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [Abstract] [Full Text] [Related]

  • 25. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
    Song SJ, Song YK, Jang M, Shin E, Suh SY, Cho YS, Lee JY, Oh JM.
    Target Oncol; 2023 Jan; 18(1):147-158. PubMed ID: 36515782
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, Smit EF.
    Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
    [Abstract] [Full Text] [Related]

  • 28. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 29. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.
    Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
    [Abstract] [Full Text] [Related]

  • 30. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.
    Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 34. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK, Bass AR.
    BMJ; 2020 Apr 06; 369():m736. PubMed ID: 32253223
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M.
    Clin Lung Cancer; 2019 Jan 06; 20(1):e97-e106. PubMed ID: 30337270
    [Abstract] [Full Text] [Related]

  • 39. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.
    J Cancer Res Clin Oncol; 2019 Feb 06; 145(2):511-521. PubMed ID: 30539281
    [Abstract] [Full Text] [Related]

  • 40. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
    Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M.
    Cancer Treat Rev; 2022 Nov 06; 110():102452. PubMed ID: 35998515
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 76.